Stoke Therapeutics
Antisense oligonucleotides that upregulate functional gene copies to treat genetic disorders
- Sector
- Biotech
- Founded
- 2014
- Latest Form D
- $90M, Nov 2018
- Total capital
- $90.8M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $90.8M
- 2 Form D · last Nov 2018
- 96 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 9
- 31 pending · first 2020
- Rank in peer group#179 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$90M
- Private capital raisedForm D · SEC · 1st filing$850K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#179 · top 12%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Adrian KrainerExecutive Officer, Director, PromoterNamed in SEC Form D filings
- Arthur A. LevinDirectorNamed in SEC Form D filings
- Arthur A. LevinDirectorNamed in SEC Form D filings
- Arthur TzianabosDirectorNamed in SEC Form D filings
- Barry TichoExecutive OfficerNamed in SEC Form D filings
- Charles R. AllersonExecutive OfficerNamed in SEC Form D filings
Show all 18 people
- Charles R. AllersonExecutive OfficerNamed in SEC Form D filings
- Edward M. KayeExecutive Officer, DirectorNamed in SEC Form D filings
- Edward M. KayeExecutive Officer, DirectorNamed in SEC Form D filings
- Gene LiauExecutive OfficerNamed in SEC Form D filings
- Huw M. NashExecutive OfficerNamed in SEC Form D filings
- Huw M. NashExecutive OfficerNamed in SEC Form D filings
- Isabel AznarezExecutive Officer, PromoterNamed in SEC Form D filings
- MeenaExecutive OfficerNamed in SEC Form D filings
- Samuel W. HallDirectorNamed in SEC Form D filings
- Samuel W. HallDirectorNamed in SEC Form D filings
- Seth L. HarrisonDirectorNamed in SEC Form D filings
- Seth L. HarrisonDirectorNamed in SEC Form D filings
What it has protected
USPTO · 9 granted of 40- New patentOPA1 Antisense Oligomers For Treatment Of Conditions And DiseasesUSPTOUS 12,753,408
- PendingAntisense Oligomers For Treatment Of Conditions And DiseasesUSPTOApplication 19542296
- PendingAntisense Oligomers For Treatment Of Conditions And DiseasesUSPTOApplication 19552066
Show all 40 patent records
- OPA1 Antisense Oligomers For Treatment Of Conditions And DiseasesOct 6, 2026 · US 12,753,408Granted
- Antisense Oligomers For Treatment Of Conditions And DiseasesSep 17, 2026 · Application 19542296Pending
- Antisense Oligomers For Treatment Of Conditions And DiseasesAug 6, 2026 · Application 19552066Pending
- Methods For Treating Conditions And DiseasesJun 18, 2026 · Application 19464440Pending
- Antisense Oligomers For Treatment Of Conditions And DiseasesMar 17, 2026 · US 12,577,561Granted
- Compounds And Methods For Treating Human SubjectsFeb 26, 2026 · Application 19372895Pending
- Antisense Oligomers For Treatment Of Non-sense Mediated Rna Decay Based Conditions And DiseasesFeb 5, 2026 · Application 18869417Pending
- Antisense Oligomers For Treatment Of Non-sense Mediated Rna Decay Based Conditions And DiseasesDec 25, 2025 · Application 19187338Pending
- Compounds For Treatment Of Conditions And DiseasesJul 31, 2025 · Application 19035483Pending
- OPA1 Antisense Oligomers For Treatment Of Conditions And DiseasesJun 24, 2025 · US 12,338,437Granted
- Methods For Treating Conditions And DiseasesFeb 27, 2025 · Application 18782724Pending
- OPA1 Antisense Oligomers For Treatment Of Conditions And DiseasesFeb 20, 2025 · Application 18658390Pending
- Methods And Compositions For Treatment Of Cholesteryl Ester Storage DiseaseAug 13, 2024 · US 12,060,558Granted
- Antisense Oligomers For Treatment Of Non-sense Mediated Rna Decay Based Conditions And DiseasesAug 1, 2024 · Application 18545753Pending
- Antisense Oligomers For Treatment Of Conditions And DiseasesMay 9, 2024 · Application 18512785Pending
- Compositions For Treatment Of Conditions And Diseases Associated With Polycystin ExpressionApr 11, 2024 · Application 18364244Pending
- OPA1 Antisense Oligomers For Treatment Of Conditions And DiseasesMar 28, 2024 · Application 18483333Pending
- Antisense Oligomers For Treatment Of Non-sense Mediated Rna Decay Based Conditions And DiseasesFeb 1, 2024 · Application 18299956Pending
- Antisense Oligomers For Treatment Of Conditions And DiseasesJan 16, 2024 · US 11,873,490Granted
- OPA1 Antisense Oligomers For Treatment Of Conditions And DiseasesNov 14, 2023 · US 11,814,622Granted
- Antisense Oligomers For Treatment Of Conditions And DiseasesApr 13, 2023 · Application 17832182Pending
- Compositions And Methods For Modulating Splicing And Protein ExpressionSep 15, 2022 · Application 17673226Pending
- Methods And Compositions For Modulating Splicing Of Alternative IntronsMay 26, 2022 · Application 17518337Pending
- Methods And Compositions For Modulating Splicing And TranslationApr 28, 2022 · Application 17518209Pending
- Antisense Oligomers For Treatment Of Autosomal Dominant Mental RETARDATION-5 And Dravet SyndromeMar 24, 2022 · Application 17356147Pending
- Antisense Oligomers For Treatment Of Non-sense Mediated Rna Decay Based Conditions And DiseasesSep 2, 2021 · Application 16758776Pending
- Antisense Oligomers For Treatment Of Autosomal Dominant Mental RETARDATION-5 And Dravet SyndromeAug 10, 2021 · US 11,083,745Granted
- Antisense Oligomers For Treatment Of Conditions And DiseasesFeb 9, 2021 · US 10,913,947Granted
- Antisense Oligomers For Treatment Of Conditions And DiseasesJun 16, 2020 · US 10,683,503Granted
- Antisense Oligomers For Treatment Of Non-sense Mediated Rna Decay Based Conditions And DiseasesApplication PCTUS2023036297Pending
- Reductive Amination For The Preparation Of Conjugated OligonucleotidesApplication 63767891Pending
- OPA1 Antisense Oligomers For Treatment Of Conditions And DiseasesApplication PCTUS2024032131Pending
- Methods For Treating Conditions And DiseasesApplication PCTUS2026013152Pending
- Methods For Treating Conditions And DiseasesApplication 63751191Pending
- Reductive Amination For The Preparation Of Conjugated OligonucleotidesApplication PCTUS2026017976Pending
- Methods For Treating Conditions And DiseasesApplication PCTUS2024039369Pending
- Methods For Treating Conditions And DiseasesApplication 63691797Pending
- Treatment Of Eye Diseases And DiagnosticsApplication PCTUS2025017947Pending
- Antisense Oligomer FormulationsApplication 63625171Pending
- Antisense Oligomer FormulationsApplication PCTUS2024015838Pending
Related companies, and why
- FORE US Bio Inc.Similar federal contract value in Biotech · null in contracts
- Inflammasome Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Terns Pharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
- Eledon Pharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
- VBI Vaccines Inc/BCSimilar federal contract value in Biotech · null in contracts
- AUKERA, INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .